Interestingly, although experimental studies have shown that targeting microglia with GLP-1R agonists has the potential to decrease retinal degeneration and neovascularization in ischemic retinopathies [140, 152], clinical trials show conflicting results with recent studies correlating GLP-1R agonists administration with worsening of DR [153–155]. Here, GLP1R is linked to retinal degeneration.